HC Wainwright Issues Optimistic Outlook for MAZE Earnings

Maze Therapeutics, Inc. (NASDAQ:MAZE) – Research analysts at HC Wainwright boosted their Q1 2026 earnings estimates for Maze Therapeutics in a note issued to investors on Wednesday, March 25th. HC Wainwright analyst A. Ghosh now forecasts that the company will post earnings of ($0.62) per share for the quarter, up from their prior estimate of ($0.73). HC Wainwright has a “Buy” rating and a $110.00 price objective on the stock. HC Wainwright also issued estimates for Maze Therapeutics’ Q2 2026 earnings at ($0.66) EPS, Q3 2026 earnings at ($0.63) EPS, Q4 2026 earnings at ($0.66) EPS, FY2026 earnings at ($2.57) EPS, FY2027 earnings at ($2.79) EPS, FY2028 earnings at ($0.57) EPS, FY2029 earnings at ($0.04) EPS and FY2030 earnings at $1.00 EPS.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings results on Wednesday, March 25th. The company reported ($0.65) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.08.

Several other equities research analysts also recently weighed in on the stock. Lifesci Capital upgraded shares of Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Wells Fargo & Company assumed coverage on Maze Therapeutics in a report on Thursday, December 4th. They set an “overweight” rating and a $55.00 price objective for the company. Weiss Ratings reissued a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Truist Financial initiated coverage on Maze Therapeutics in a research note on Tuesday, March 17th. They set a “buy” rating and a $68.00 target price on the stock. Finally, Guggenheim upped their target price on Maze Therapeutics from $46.00 to $58.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $64.11.

Maze Therapeutics Stock Down 4.2%

NASDAQ MAZE opened at $30.38 on Friday. The firm has a market cap of $1.51 billion, a PE ratio of -9.41 and a beta of 4.47. The company has a 50 day moving average price of $45.61 and a 200 day moving average price of $37.62. Maze Therapeutics has a 52 week low of $6.71 and a 52 week high of $53.65.

Institutional Trading of Maze Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its stake in Maze Therapeutics by 128.3% during the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after purchasing an additional 363 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Maze Therapeutics in the fourth quarter worth about $39,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Maze Therapeutics in the fourth quarter worth about $43,000. California State Teachers Retirement System lifted its holdings in shares of Maze Therapeutics by 138.0% during the fourth quarter. California State Teachers Retirement System now owns 1,321 shares of the company’s stock worth $55,000 after purchasing an additional 766 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its position in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the last quarter.

Insider Buying and Selling at Maze Therapeutics

In other news, insider Atul Dandekar sold 72,400 shares of the business’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the sale, the insider directly owned 10,503 shares of the company’s stock, valued at $426,001.68. The trade was a 87.33% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CMO Harold Bernstein sold 45,000 shares of the business’s stock in a transaction on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 245,000 shares of company stock worth $10,504,792.

Key Stories Impacting Maze Therapeutics

Here are the key news stories impacting Maze Therapeutics this week:

• Positive Sentiment: HC Wainwright materially raised near‑term EPS estimates across 2026–2029 and boosted FY2030 to $1.00 while maintaining a “Buy” rating and a $110 price target — a strong analyst endorsement that supports upside if development and regulatory paths stay on track. HC Wainwright Boosts Maze Therapeutics (NASDAQ:MAZE) Price Target to $110.00
• Positive Sentiment: BTIG issued a “Buy” rating, adding further sell‑side support that could attract buyers looking for durable conviction from institutional analysts. Maze Therapeutics (NASDAQ:MAZE) Earns “Buy” Rating from BTIG Research
• Positive Sentiment: Phase 2 HORIZON data for MZE829 showed a clinically meaningful ~35.6% mean reduction in proteinuria (uACR), exceeding the ≥30% threshold cited for regulatory relevance — the fundamental clinical readout supports a pathway toward a pivotal trial. Maze Therapeutics: MZE829 Presses Forward Despite Stock Price Drop
• Neutral Sentiment: Technical metrics show the stock moved into oversold territory after the selloff, and some analysts/technicals argue the decline may have exhausted short‑term sellers — this could set up a technical bounce independent of fundamentals. After Plunging 30.8% in 4 Weeks, Here’s Why the Trend Might Reverse for Maze Therapeutics
• Negative Sentiment: Despite positive efficacy, the market treated the Phase 2 results as “mixed” on endpoints/subgroup/readout detail, triggering a steep selloff that wiped nearly a third of market value — heightened volatility and investor uncertainty remain key near‑term risks. Maze Loses Nearly a Third of Market Cap on Mixed Midstage Kidney Drug Data
• Negative Sentiment: A shareholder law firm (Johnson Fistel) has opened an investigation into potential claims related to MAZE disclosures — this introduces legal/PR risk and could prolong downward pressure if it results in litigation or heightened scrutiny. MAZE Shareholders Are Encouraged to Reach Out to Johnson Fistel
• Negative Sentiment: Media coverage captured the paradox of “best‑in‑class potential” commentary alongside a sharp post‑readout plunge, amplifying sentiment swings and increasing short‑term trading risk. After ph. 2 readout, analysts herald best‑in‑class potential as stock plummets

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.